Novartis, Aduro Ink $750M Cancer Drug Development Deal
Swiss drugmaker Novartis AG forged a partnership with pancreatic cancer immunotherapy developer Aduro Biotech Inc., agreeing Monday to pay up to $750 million as venture capital-backed Aduro advances its drug pipeline...To view the full article, register now.
Already a subscriber? Click here to view full article